Appropriate empirical antibacterial therapy for nosocmial infections - Getting it right the first time

被引:109
作者
Kollef, MH [1 ]
机构
[1] Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA
关键词
D O I
10.2165/00003495-200363200-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The increasing presence of drug-resistant bacterial infections among hospitalised patients has resulted in greater numbers of patients receiving inappropriate antimicrobial treatment. This has led to the development of a novel paradigm guiding the administration of empirical antimicrobial therapy for patients with serious infections in the hospital setting. Antibacterial de-escalation is an approach to antibacterial utilisation that attempts to balance the need to provide appropriate, initial antibacterial treatment while limiting the emergence of antibacterial resistance. The goal of de-escalation is to prescribe an initial antibacterial regimen that will cover the most likely bacterial pathogens associated with infection while minimising the emergence of antibacterial resistance. Antibacterial resistance is minimised by narrowing the antibacterial regimen once the pathogens and their susceptibility profiles are determined, and by employing the shortest course of therapy clinically acceptable.
引用
收藏
页码:2157 / 2168
页数:12
相关论文
共 64 条
[1]   Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit [J].
AlvarezLerma, F ;
Pellus, AM ;
Sanchez, BA ;
Ortiz, EP ;
Jorda, R ;
Barcenilla, F ;
Maravi, E ;
Galvan, B ;
Palomar, M ;
Serra, J ;
Bermejo, B ;
Mateu, A ;
Quintana, E ;
Palacios, MS ;
Giral, R ;
Gonzalez, V ;
Lerma, FA ;
Mesa, JL ;
Melgarejo, JA ;
Martinez, J ;
Insausti, J ;
Olaechea, P ;
Chanovas, M ;
Gilabert, A ;
Junquera, C ;
Valles, J ;
Palacios, F ;
Calvo, R ;
Mesalles, E ;
Nava, J ;
Santos, A ;
Armengol, S ;
Marzo, D .
INTENSIVE CARE MEDICINE, 1996, 22 (05) :387-394
[2]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[3]  
Bailey TC, 1997, PHARMACOTHERAPY, V17, P277
[4]  
Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711
[5]   Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa [J].
Carmeli, Y ;
Troillet, N ;
Karchmer, AW ;
Samore, MH .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) :1127-1132
[6]  
CHASTRE J, 2003, AM J RESP CRIT CARE, V167, pA21
[7]   ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY [J].
CHOW, JW ;
FINE, MJ ;
SHLAES, DM ;
QUINN, JP ;
HOOPER, DC ;
JOHNSON, MP ;
RAMPHAL, R ;
WAGENER, MM ;
MIYASHIRO, DK ;
YU, VL .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) :585-590
[8]   PROSPECTIVE RANDOMIZED COMPARISON OF IMIPENEM MONOTHERAPY WITH IMIPENEM PLUS NETILMICIN FOR TREATMENT OF SEVERE INFECTIONS IN NONNEUTROPENIC PATIENTS [J].
COMETTA, A ;
BAUMGARTNER, JD ;
LEW, D ;
ZIMMERLI, W ;
PITTET, D ;
CHOPART, P ;
SCHAAD, U ;
HERTER, C ;
EGGIMANN, P ;
HUBER, O ;
RICOU, B ;
SUTER, P ;
AUCKENTHALER, R ;
CHIOLERO, R ;
BILLE, J ;
SCHEIDEGGER, C ;
FREI, R ;
GLAUSER, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1309-1313
[9]   Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species [J].
Cosgrove, SE ;
Kaye, KS ;
Eliopoulous, GM ;
Carmeli, Y .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (02) :185-190
[10]   Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia [J].
Dennesen, PJW ;
van der Ven, AJAM ;
Kessels, AGH ;
Ramsay, C ;
Bonten, MJM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (06) :1371-1375